In contrast, spontaneous IL-10 production by CLL samples reached the order of 1000 pg/ml following stimulation with IL-2 and resiquimod and was strikingly reduced by ruxolitinib, particularly in TLR-activated cells (Figure 2C and Supplementary Figure 4A). This evidence concerns the gene IL10 and B-cell chronic lymphocytic leukemia.